Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announce...
Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price targ...
Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price ta...
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the ...
Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight and raises the price target...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $87 t...
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from...
